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Abstract
Objective: This article aims to review the clinical features and therapeutic characteristics 
that may predict treatment response in patients with social anxiety disorder (SAD). Methods: 
A systematic review of trials identified through databases of ISI, Medline, PsycInfo, Cochrane, 
LILACS, Current Controlled Trials, and in references of previously selected articles published in 
English up to December 2010. In our literature search, we used the words prediction/predictors 
and social anxiety disorder or social phobia. Results: Early onset, greater disease severity, 
comorbidity with other anxiety disorders (including generalized anxiety disorder and simple 
phobia), and high expectations about the role of the therapist emerged as potential predictors 
of less effective treatment in SAD. Conclusions: Knowledge of various clinical and treatment 
features may help professionals to predict possible responses to therapeutic interventions in 
patients with SAD. However, given the diversity of measures used to assess response, further 
studies should be performed with standardized methods to investigate the aspects related to 
treatment resistance in SAD.
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93A review on predictors of treatment outcome in social anxiety disorder
Uma revisão sobre fatores de predição de resposta ao tratamento no transtorno de 
ansiedade social
Resumo
Objetivo: Este artigo tem por objetivo descrever as principais características clínicas e terapêuticas 
que possam predizer resposta ao tratamento em pacientes com transtorno de ansiedade social 
(TAS). Métodos: Revisão sistemática de ensaios clínicos identificados através das bases de 
dados ISI, Medline, PsycInfo, Cochrane, LILACS, Current Controlled Trials e em referências 
bibliográficas de artigos previamente selecionados publicados em inglês até dezembro de 2010. 
As seguintes palavras-chave foram utilizadas em nossa busca bibliográfica: prediction/predictors 
e social anxiety disorder ou social phobia. Resultados: Início precoce, maior gravidade da 
doença, comorbidade com outros transtornos de ansiedade (incluindo o transtorno de ansiedade 
generalizada e fobia simples) e alta expectativa sobre o papel do terapeuta emergiram como 
potenciais fatores de predição menor eficácia do tratamento do TAS. Conclusões: O conhecimento 
de uma variedade de características clínicas e de tratamento pode auxiliar os profissionais a 
preverem possíveis respostas às intervenções terapêuticas nos pacientes com TAS. No entanto, 
devido à diversidade de medidas utilizadas para avaliar a resposta, novos estudos com o objetivo 
de investigar aspectos relacionados à resistência ao tratamento do TAS devem ser realizados com 
métodos mais padronizados. 
©2012 Elsevier Editora Ltda. Todos os direitos reservados.
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Introduction
Social anxiety disorder (SAD) is characterized by intense 
and persistent fear of being negatively evaluated by others, 
which leads to significant avoidance or intense psychological 
distress in various social situations.1 SAD has high prevalence 
rates, early and insidious onset, and a chronic course.2 It is as-
sociated with low levels of quality of life; significant feelings 
of incapacity; and notorious social, educational, and occupa-
tional disability.3 Despite remaining largely underdiagnosed,4 
recent studies are beginning to unveil SAD neurobiological 
underpinnings, thus leading to greater knowledge regarding 
its pathophysiology.5
Currently, the most empirically effective treatments of SAD 
include pharmacotherapy with selective serotonin reuptake 
inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibi-
tors (SNRIs), and cognitive behavioral therapy (CBT), either 
together or separately.6,7,8 Although these strategies lead to 
a therapeutic response in a large proportion of individuals, a 
significant number of patients with SAD (up to 50%) does not 
respond at all or remain significantly symptomatic after being 
submitted to first-line treatments.9,10,11 
This article aims to review the clinical and therapeutic 
characteristics that have been reported to be associated 
with response to treatment prescribed to patients with SAD. 
Potentially, the characterization of these features may save 
patients’ time by avoiding ineffective treatments, which may 
be sometimes associated with severe side effects and/or 
economic burden. It could also help to identify factors that 
should be taken into account if one aims at elaborating more 
specific treatment for SAD individuals who do not respond to 
conventional strategies.
Methods
A systematic review of clinical trials that describe the 
profile of patients with SAD who respond to treatment was 
performed in the following databases: ISI/Web of science, 
Medline, PsycInfo, Cochrane Library, LILACS, and Current 
Controlled Trials (articles not published yet). An additional 
search for articles of interest was performed in the biblio-
graphic list of selected articles. The following keywords were 
used in the bibliographical search: prediction/predictors 
and social anxiety disorder or social phobia. Clinical trials 
originally published in English up to December 2010 were 
assessed. 
Inclusion criteria consisted of studies composed of sub-
jects with a primary diagnosis of SAD according to the DSM-
III-R or DSM-IV and describing an assessment of treatment 
response predictors in this condition. We included papers 
that addressed the following aspects as potential response 
predictors: (i) clinical features (age of onset, duration of 
SAD, severity of symptoms, generalized subtype of SAD, 
family history of SAD, and psychiatric comorbidity); (ii) socio-
demographic characteristics (age, gender, educational level, 
and marital status); and (iii) treatment features (treatment 
history, duration of current treatment, expectancy regarding 
treatment, and group cohesion [in case of group therapy]). 
For the sake of space, other potential predictors (e.g., per-
sonality traits) were not addressed in our review.
Results
Medline search identified 392 articles, of which 10 met the 
inclusion criteria. In PsycInfo, from the 58 studies identified, 
5 were included. The ISI/Web of Science database led to the 
identification of 679 articles, of which 4 were included. A 
Cochrane search resulted in 158 studies, of which 11 were 
selected, including 10 that had already been localized on 
Medline and Psyinfo, and one that appeared for the first time. 
A LILACS search led to only one article, which did not 
meet the inclusion criteria. Unpublished articles searched 
on Current Controlled Trials were not found as well. Four 
additional articles were identified in the reference lists 
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of previously selected articles. These combined search 
strategies led to a total of 24 selected articles. Most stud-
ies (n = 19) reported independent predictors of response 
using regression analysis, while the remaining ones12-16 used 
univariate analysis. 
Clinical characteristics
Studies describing the impact of different clinical character-
istics (including age of onset, duration, symptom severity, 
subtype, and family history) on SAD treatment outcomes are 
listed in Table 1.
Age of onset
The impact of the age of SAD onset on treatment outcome 
was investigated in four studies. In one of them, no impact 
of age of onset on the response of 57 patients treated with 
group CBT was found.17 In the second trial with 204 patients 
treated with sertraline or placebo, patients with late-onset 
(≥ 19 years) generalized SAD tended to have a better response 
to treatment with sertraline than those with early-onset gen-
eralized SAD.18 Accordingly, in two additional studies; e.g., 
one including 102 patients with generalized SAD submitted 
to individual or group CBT19 and the other including 80 SAD 
patients treated with individual and group cognitive or in-
terpersonal therapy,20 early (childhood) onset emerged as a 
predictor of poor response to treatment. 
Duration of illness
Duration of SAD was not associated with a worse therapeutic 
outcome in four studies, including trials with moclobemide,21 
brofaromine and fluvoxamine,22 paroxetine,23 and group CBT.17 
Only one placebo-controlled trial found baseline duration of 
generalized SAD to be a significant predictor of poor response 
to treatment (in this case, sertraline).24 In this study, none 
of the independent variables were significant as predictors of 
response to placebo.
Severity
The impact of SAD severity on treatment outcome was ana-
lyzed in three studies.22,23,25 Increased severity of symptoms 
predicted worse response in 30 patients treated with bro-
faromine or fluvoxamine (with higher Symptom Checklist-90 
interpersonal sensitivity scores and heart rate predicting 
92% of non-responders),22 and in 76 patients submitted 
Table 1 Studies describing the impact of different clinical characteristics on treatment outcomes of social anxiety disorder
Study Design Intervention N Clinical characteristics Influence on response
Brown et al.28 Controlled clinical trial CBTG
ESTG 
PHE 
PLO
NI Generalized subtype Negative
Slaap et al.22 Controlled clinical trial BROFARO
FLUVO
15
15
Short duration of SAD
Greater Severity
Generalized subtype
Family history
Neutral
Negative
Neutral
Negative
Turner et al.12 Controlled clinical trial Flooding 
ATE
PLO
NI Generalized subtype Neutral
Versiani et al.21 Naturalistic MCLO 93 Short duration of SAD
Generalized subtype
Neutral
Negative
Scholing et al.25 Open trial CBTG and/or individual 73 Greater Severity Negative
Van Ameringen et al.24 Controlled clinical trial SERT 
PLO
NI Short duration of SAD Positive
Stein et al.23 Controlled clinical trial PARO
PLO
491
329
Short duration of SAD
Greater Severity
Neutral
Neutral
Van Ameringen et al.18 Controlled clinical trial SERT
PLO
NI Early onset of SAD Negative
Lincoln et al.26 Naturalistic CBTG 287 Generalized subtype Negative
Chen et al.17 Open trial CBTG 57 Early onset of SAD
Short duration of SAD
Generalized subtype
Neutral
Neutral
Neutral
Dalrymple et al.19 Open trial CBTG and/or individual 102 Early onset of SAD Negative
Marom et al.27 Naturalistic trial CBTG 219 Generalized subtype Negative
Borge et al.20 Controlled clinical trial COTG and individual
IT individual and group
40
40
Early onset of SAD Negative
ATE: Atenolol; BROFARO: Brofaromine; CBTG: Cognitive Behavior Therapy Group; ESTG: Educational Supportive Therapy group; FLUVO: Fluvoxamine; 
IT: Interpersonal Therapy; MCLO: Moclobemide; NI: Not Informed; PARO: Paroxetina; PLO: Placebo; SAD: Social Anxiety Disorder; SERT: Sertraline; 
PHE: Phenelzine; COTG: Cognitive Therapy In Group.
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to individual or group CBT25 (with greater impairment or 
Global Clinician rating of Social Phobia severity predicting a 
slight proportion [4-8%] of treatment outcome). In the third 
study,23 the severity levels (according to the baseline scores 
on the Liebowitz Social Anxiety Scale) of 829 SAD patients 
did not predict differences in outcome after treatment with 
paroxetine or placebo.
Subtype 
No differences in terms of response to treatment was found 
between generalized and non generalized SAD patients in 
three clinical trials: one article with brofaromine or fluvox-
amine,22 one involving group CBT,17 and one comparing ateno-
lol to exposure psychotherapy (EXP) with flooding.12 However, 
in other four studies using group CBT,26,27 moclobemide,21 
or a set of interventions (including group CBT, educational 
support therapy, phenelzine, and placebo pill),28 generalized 
SAD patients exhibited worse response to treatment com-
pared to non-generalized patients in the post-test. In one 
of these studies, the generalized subtype was characterized 
by a trend towards worse short-term response in group CBT, 
although this difference reached statistical significance after 
one-year of follow up.26 
Family history 
Only one article suggested that the presence of a family 
history of SAD predicts worse response to treatment with 
brofaromine or fluvoxamine in SAD patients.22 Therefore, the 
relationship between family history and response to treat-
ment should be considered relatively fragile at this moment.
Comorbidities
Studies describing the impact of different psychiatric comor-
bidities (including personality, anxiety and mood disorders, 
and substance abuse) on SAD treatment outcomes are de-
picted in Table 2.
Personality disorders
Eleven trials assessed the influence of avoidant personality 
disorder (PD) on treatment response of patients with SAD. 
In five of these studies, patients with SAD and avoidant PD 
displayed worse outcome after treatment (including mo-
clobemide,21 atenolol or EXP with flooding,12 group CBT,29 
EXP,13 and moclobemide or individual cognitive therapy)30 
compared to patients with SAD without avoidant PD. 
Nonetheless, in one of these studies,30 this difference did 
not remain significant after 15 months of treatment.
In five additional articles, the comorbidity of SAD with 
avoidant PD did not predict differences in response to inter-
ventions with sertraline,18 EXP,14 individual or group CBT,25 
individual or group cognitive therapy, individual or group 
interpersonal therapy20 and a set of interventions (includ-
ing group CBT, educational support therapy, phenelzine 
and placebo pill).28 Finally, in contrast to the results described 
above, a study with 295 generalized SAD patients re-
ported that patients with avoidant personality disorder (APD) 
had exhibited greater changes in SAD early in treatment than 
those without APD.15 
Two studies reported that other types of PD (e.g., obses-
sive-compulsive and dependent) had no influence in response 
of 84 SAD patients who received either atenolol or EXP with 
flooding treatment,12 and 93 SAD patients who were treated 
with moclobemide.21 Histrionic PD co-morbidity with SAD, 
on the other hand, had a negative impact on response to 
treatment with atenolol or EXP with flooding.12 
Anxiety disorders
A study with 52 SAD patients treated with group CBT plus 
video feedback of exposures revealed that co-morbidity with 
any anxiety disorder was associated with a worse therapeutic 
outcome.31 Similarly, the presence of simple phobia had a 
negative impact on treatment response of 84 patients with 
SAD treated with atenolol or EXP with flooding.12 Finally, 
generalized anxiety disorder (GAD) was associated with 
worse treatment response of 93 patients with SAD treated 
with moclobemide,21 and of 84 patients treated with atenolol 
or EXP with flooding.12
Mood disorders
The influence of comorbid mood disorders on the treatment 
outcome of patients with SAD was associated with mixed 
results. For instance, in at least three studies,25,26,29 the 
presence of major depression was associated with worse 
response of SAD patients treated with group and individual 
CBT25 or group CBT,26,29 respectively. Similarly, comorbid 
dysthymia had a negative impact on response to treatment 
with atenolol or EXP with flooding12 and with moclobemide.21 
However, in one of these articles, the negative influence of 
depression on the therapeutic outcome was not maintained 
in the 18-month follow up.25 
In two trials27,32 no difference was found in the post-test 
of SAD patients with comorbid depression treated with group 
CBT. However, in one of these studies,27 patients with SAD 
and comorbid depression displayed an increased relapse rate 
after one year. On the other hand, the presence of previous 
episode of depression in patients treated with moclobemide 
did not predict any difference in treatment outcome.21 
Alcohol abuse
In one of the studies described above,21 the occurrence of 
alcohol abuse co-morbidity was by far the strongest predic-
tor of worse therapeutic outcome in 93 SAD patients treated 
with moclobemide.
Sociodemographic characteristics
Studies describing the impact of different sociodemographic 
features (including age, gender, educational level, and mari-
tal status) on SAD treatment outcomes are listed in Table 3.
Age
According to several aforementioned studies, the patient’s 
age did not predict the therapeutic response of SAD patients 
to sertraline,18 moclobemide,21 paroxetine,23 brofaromine or 
fluvoxamine,22 group CBT,17,32 and group or individual CBT.19
Gender
Similarly, no impact of gender on treatment response of SAD 
patients was found in most trials reviewed above, including 
studies that used group CBT,17 group or individual CBT,19 
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paroxetine,23 moclobemide,21 brofaromine or fluvoxamine.22 
In one naturalistic study, no difference regarding treatment 
outcomes was found when CGI scores of both genders were 
compared at the end-point after treatment with SSRIs and/
or benzodiazepines.16 However, male gender was associated 
with worse response of SAD patients to sertraline or placebo18 
and to group plus video feedback CBT.31 
Educational/Marital status
Educational and marital status had no impact on the response 
of 57 SAD patients in group CBT in one study,17 and of 102 pa-
tients treated with group or individual CBT in another one.19 
Treatment characteristics
Studies describing the impact of different therapeutic fea-
tures on the outcome of SAD (including history, duration and 
expectancy of current treatment, and group cohesion [in case 
of group therapy]) are listed in Table 4.
Previous treatment
In three aforementioned studies, previous treatment (either 
pharmacotherapy or psychotherapy) had no impact on the 
response of SAD patients to moclobemide,21 brofaromine and 
fluvoxamine,22 and in group CBT.17
Table 2  Studies describing the impact of different comorbidities on treatment outcomes of social anxiety disorder
Study Design Intervention N Comorbidities Influence on response
Brown et al.28 Controlled clinical trial CBTG
ESTG
PHE
PLO
NI Avoidant PD Neutral
Turner et al.12 Controlled clinical trial Flooding
ATE
PLO
NI Avoidant PD
Obsessive Compulsive PD
Dependent PD
Histrionic PD
GAD
Simple Phobia
Dysthimia
Negative
Neutral
Neutral
Negative
Negative
Negative
Negative
Versiani et al.21 Naturalistic trial MCLO 93 Avoidant PD
Obsessive Compulsive PD
Dependent PD
GAD
Dysthimia
Previous Depression
Alcohol Abuse
Negative
Neutral
Neutral
Negative
Negative
Neutral
Negative
Chambless et al.29 Open trial CBTG 62 Avoidant PD
Depression
Negative
Negative
Feske et al.13 Naturalistic trial EXP 48 Avoidant PD Negative
Van Velzen et al.14 Open trial EXP 61 Avoidant PD Neutral
Scholing et al.25 Open trial CBTG and/or individual 73 Avoidant PD
Depression
Neutral
Negative
Oosterbaan et al.30 Controlled clinical trial COT individual 
MCLO
PLO
28
27
27
Avoidant PD Negative
Van Ameringen et al.18 Controlled clinical trial SERT 
PLO
NI Avoidant PD Neutral
Lincoln et al.26 Naturalistic trial CBTG 287 Depression Negative
Huppert et al.15 Controlled clinical trial FLU
CBTG
FLU+CBTG
CBTG+PLO
NI Avoidant PD Positive
Marom et al.27 Naturalistic trial CBTG 219 Depression Neutral
Alfano et al.32 Controlled clinical trial CBTG 
TNE
NI Depression Neutral
Chen et al.31 Open trial CBTG+VF 52 Anxiety Disorders Negative
Borge et al.20 Controlled clinical trial COTG and individual
IT individual and group
40
40
Avoidant PD Neutral
ATE: Atenolol; CBTG: Cognitive Behavior Therapy Group; EXP: exposure psychotherapy; COT: Cognitive Therapy; COTG: Cognitive Therapy In Group; 
ESTG: Educational Supportive Therapy Group; FLU: Fluoxetine; GAD: Generalized Anxiety Disorder; IT: Interpersonal Therapy; MCLO: Moclobemida; NI: Not 
Informed; PD: Personality Disorder; PHE: Phenelzine; PLO: Placebo; SERT: Sertraline; TNE: Treatment not Specific; VF: Video feedback.
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Table 3 Studies describing the impact of different sociodemographic features the treatment outcomes of social anxiety disorder
Study Design Intervention N Sociodemographic 
characteristics
Effect on response
Slaap et al.22 Controlled clinical Trial BROFARO 
FLUVO
15
15
Age
Gender
Neutral
Neutral
Versiani et al.21 Naturalistic trial MCLO 93 Age
Gender
Neutral
Neutral
Stein et al.23 Controlled clinical Trial PARO 
PLO
491
329
Age
Gender
Neutral
Neutral
Van Ameringen et al.18 Controlled clinical Trial SERT 
PLO
NI Age
Female Gender
Neutral
Positive
Chen et al.17 Open trial CBTG 234 Age
Gender
Educational
Marital status
Neutral
Neutral
Neutral
Neutral
Dalrymple et al.19 Open trial CBTG and/or individual 57 Age
Gender
Educational
Marital status
Neutral
Neutral
Neutral
Neutral
Menezes et al.39 Naturalistic trial SSRI and/or BENZO 34 Gender Neutral
Alfano et al.32 Controlled clinical Trial CBTG 
TNS
NI Age Neutral
Chen et al.31 Open trial CBTG+VF 80 Male Gender Negative
BENZO: Benzodiazepine; BROFARO: Brofaromine; CBTG: Cognitive Behavior Therapy Group; FLUVO: Fluvoxamine; MCLO: Moclobemide; NI: Not Informed; 
PARO: Paroxetine; PLO: Placebo; SERT: Sertraline; SSRI: selective serotonin reuptake inhibitors; TNS: Treatment not Specific; VF: Video feedback.
Table 4  Studies describing the impact of different treatment characteristics on treatment outcomes of social anxiety disorder
Study Design Intervention N Treatment characteristics Effect on Response
Slaap et al.22 Controlled clinical trial BROFARO 
FLUVO
15
15
Previous treatment Neutral
Versiani et al.21 Naturalistic MCLO 93 Previous treatment Neutral
Chambless et al.29 Open trial CBTG 62 Low expectancy regarding
treatment effectiveness
Negative
Stein et al.23 Controlled clinical trial PARO
PLO
491
329
Short duration of treatment Negative
Erwin et al.33 Controlled clinical trial CBTG 234 Low expectancy regarding treatment 
effectiveness
Negative
Chen et al.17 Open trial CBTG 57 Previous treatment
Short duration of treatment
Neutral
Neutral
Taube-Schiff et al.35 Open trial CBTG 34 Group cohesion Positive
Delsignore et al.34 Open trial CBTG 49 Low expectancy regarding
the therapist role
Neutral
Borge et al.20 Controlled clinical trial COTG and individual
IT individual and group
40
40
Low expectancy regarding
treatment effectiveness
Negative
BROFARO: Brofaromine; CBTG: Cognitive Behavior Therapy Group; COTG: Cognitive Therapy in Group; FLUVO: Fluvoxamine; IT: Interpersonal Therapy; 
MCLO: Moclobemide; PARO: Paroxetine, PLO: Placebo.
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Duration of treatment
In a study with 829 SAD patients,23 treatment with paroxetine 
for 12 weeks was associated with increased response com-
pared to treatment for only 8 weeks. Conversely, another 
study that used group CBT with a protocol of 11-20 sessions 
found that the number of treatment sessions did not predict 
response of 57 patients with SAD.17 
Expectancy regarding treatment effectiveness
Low expectancy regarding treatment effectiveness and 
reduced confidence concerning treatment predicted worse 
response in studies that comprised 6229 and 234 patients33 
with SAD assigned to group CBT, and 80 patients with SAD 
assigned to cognitive therapy or interpersonal therapy.20 
Expectancy regarding the therapist role
In one study, the expectations of 49 SAD patients about the 
role of the therapist in their treatment did not have any 
influence on their response in group CBT in the short-term.34 
However, in the three-month follow up, patients who attrib-
uted greater responsibility for change to their therapists had 
worse therapeutic response. 
Group cohesion in group CBT
The perception of group cohesion of individuals attending 
group CBT and its impact on treatment outcome were studied 
in 34 patients with SAD.35 In this study, increases in group 
cohesion ratings over the course of treatment significantly 
predicted therapeutic response. 
Discussion
The present work aimed at reviewing the overall profile of 
individuals with SAD who respond and not respond to stan-
dard treatment, with the ultimate purpose of contributing 
to future research on the development of more effective 
interventions.36 We found that early onset, increased dura-
tion and severity of illness, presence of generalized subtype, 
positive family history of SAD, and male gender were all 
predictors of worse response to treatment in at least one 
study. Among these, early onset and severity of illness were 
the most replicated findings. 
In terms of co-morbidity, major depression, dysthymia, 
generalized anxiety disorder, simple phobia, avoidant and 
histrionic PD, and alcohol abuse predicted negative responses 
to treatment in at least one trial. Among these conditions, 
anxiety disorders emerged as a predictor of poor therapeutic 
response in more than one study. 
Finally, regarding treatment characteristics, low expec-
tancy regarding treatment efficacy, high expectancy regard-
ing the role of the therapist in treatment, and decreased 
group cohesion (in case of group cognitive behavioral treat-
ment) were associated with worse therapeutic responses. 
Among the later, low expectancy regarding treatment ef-
ficacy was the most replicated finding.
Importantly, we found a handful of studies suggesting the 
association between early onset of SAD and poor response to 
treatment. While this finding provides some support to the 
view that the early-onset of SAD represents a valid subtype 
of SAD, with greater psychiatric comorbidity, higher levels of 
incapacitation, and worse prognosis,19 there is still contro-
versy on this subtype definition, as different studies used 
different age criteria for “early” or “late” onset. Previous 
reviews suggested that the unwelcome influence of both age 
at onset and severity of symptoms on treatment outcome 
holds true for other anxiety disorders.37 
Furthermore, we also found some evidence that greater 
severity of social anxiety symptoms predicts decreased ef-
ficacy in the response of patients with SAD to different types 
of treatment (both pharmacotherapy and psychotherapy). 
This finding is particularly relevant when one considers that 
all studies reporting them focused their analysis on patients 
who completed treatment (and not on an intention-to-
treat sample), thus suggesting that decreased treatment 
efficacy cannot be ascribed to the tendency that patients 
with more severe symptoms have to discontinue treatment 
more frequently. 
Data supporting an effect of comorbid psychiatric disor-
ders in SAD treatment response are mixed, particularly for 
depression. It is difficult to explain these findings because, 
while major depression and dysthymia could perpetuate and 
strengthen SAD patients negative beliefs about themselves, 
some of the SAD treatments (including SSRIs and cognitive 
re-structuring) may effectively treat some forms of depres-
sion, particularly those that are secondary. Accordingly, it is 
interesting to note that many of the comorbid conditions found 
to predict worse response of SAD to treatment (e.g., alcohol 
abuse,21 specific phobia,12 histrionic PD12) are not clearly 
responsive to treatment (e.g., antidepressants) themselves. 
It is worth noting that findings regarding the role of several 
comorbid conditions were assessed in only one study, which 
restrains us to consider these results as conclusive.
Finally, we also found that low expectancy regarding 
treatment effectiveness,29 which might be related to co-
morbid depression,38 was associated with worse response to 
treatment in different studies. Clearly, patients with SAD 
might believe that the treatment will not work in their case, 
that they will not be able to follow the therapeutic steps, 
or that another person will be totally responsible for his im-
provement. These cognitive distortions should be identified 
and managed early in the treatment. 
Conversely, lower expectations about the role of the 
therapist were related to better treatment outcomes, par-
ticularly in the follow-up sessions.34 Likewise, in one study, 
increased feelings of group cohesion between participants 
and therapist in group CBT was associated with better 
outcomes.35 It would be interesting to test whether add-on 
strategies (aimed at increasing treatment expectancy, at-
tributing responsibility for change to patients, and stressing 
the importance of group cohesion in group CBT) increase the 
effectiveness of treatment provided to patients with SAD. 
Indeed, our review has a number of limitations. First, 
several sociodemographic and clinical variables associated 
with worse outcomes (e.g., previous treatment, dependent 
and obsessive compulsive PD comorbidity) had their rela-
tionship with outcome assessed by a very small number of 
studies. Second, as there is no current consensus on what 
should be the optimal criteria for treatment response in 
SAD, one should examine our results with caution.12,25,29 It 
has been argued that the concept of response and remis-
sion in SAD must be multidimensional,39 embracing the 
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reappraisal of the diagnosis,40 social anxiety symptoms, 
and comorbid conditions.36 Of note, none of the reviewed 
studies adopted such criteria. Third, there is a clear meth-
odological heterogeneity among selected studies, including 
study design,15,17,23 type of intervention,21,25-27,29,32 and dura-
tion of treatment (varying from five or seven days26 to two 
years).21 Accordingly, one must consider that, regardless of 
treatment, longer follow-ups are usually associated with 
substantial reduction in anxiety symptoms, a phenomenon 
that can be explained by the tendency of SAD individuals 
to orientate their life choices so that anxiogenic situations 
become less prominent.41
Conclusion
The recent increase in the number of studies in the field 
of response and resistance in SAD is complicated by the 
difficulty of replicating and comparing these studies. Even 
when they are conducted with similar patients, treatment, 
and methods, a considerable variety of treatment response 
and resistance definitions is used.25 As a consequence, the 
current sociodemographic and clinical profile of SAD patients 
who respond to treatment remains elusive, as it does not 
point to a very clear direction. 
To date, early onset, severity of illness, comorbid anxi-
ety disorders (particularly generalized anxiety disorder and 
simple phobia), and low expectancy regarding treatment 
efficacy emerged as potential correlates and/or predictors 
of low therapeutic response. Clearly, the field of treatment 
response needs conceptual and methodological redefinitions 
if it aims to lead to more solid results. A better knowledge 
about the profile of the significant proportion of SAD patients 
who remain resistant to treatment is important for discuss-
ing the emergence of novel therapeutic alternatives, both 
in terms of psychotherapy and pharmacotherapy.
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